LAG3 and neoplasm: Since genome editing technologies, such as CRISPR-Cas9 and TALEN, are available for human peripheral blood-derived T cells, researchers have knocked out T cell inhibitory molecules, such as PD-1, lymphocyte activation gene 3 protein (LAG-3), and adenosine A2A receptor (A2AR), and reported enhanced CAR-T cell anti-tumor efficacy in xenograft models in vivo [110,111,112].